NeuroSense Therapeutics Ltd. NRSNW
0.01 USD +0.01 (+72.00%)
Nov 4, 2026, 3:55 PM EST
0.0099 Day range 0.013
0.0099 52-week range 0.013
- YTD
- +72.00%
- 1 year
- +72.00%
News
benzinga.com NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term…- benzinga.com NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027 NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative…
defenseworld.net NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW - Get Free Report) saw a significant drop in short interest in December. As of December 15th, there was short interest totaling 9,001 shares, a drop of…